PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2021 Financial Results
31 mars 2022 07h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted...
PDS Biotechnology Reschedules 2021 Fourth Quarter and Full Year Financial Results and Conference Call
22 mars 2022 19h30 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease...
PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers
15 mars 2022 07h45 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing molecularly-targeted cancer therapies and...
PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter and Full Year 2021 Financial Results
09 mars 2022 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease...
PDS Biotechnology to Present at the 32nd Oppenheimer Annual Healthcare Conference
01 mars 2022 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease...
PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium
24 févr. 2022 10h10 HE
|
PDS Biotechnology Corporation
Preliminary safety data has shown that PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer...
PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer
15 févr. 2022 08h00 HE
|
PDS Biotechnology Corporation
The study evaluates PDS0101 with and without KEYTRUDA® prior to surgery for HPV-associated oropharyngeal cancer FLORHAM PARK, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation...
PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer
02 févr. 2022 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Feb. 02, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease...
PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine
27 janv. 2022 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Jan. 27, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease...
PDS Biotechnology to Present at B. Riley Securities Virtual Oncology Conference
18 janv. 2022 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease...